Document:

EXHIBIT 10.29

                                     WARRANT

THE  WARRANT  REPRESENTED  BY THIS  CERTIFICATE  AND THE  SHARES  ISSUABLE  UPON
EXERCISE  HEREOF HAVE NOT BEEN  REGISTERED  UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE "ACT"), OR ANY STATE SECURITIES LAWS IN RELIANCE ON EXEMPTIONS FROM
REGISTRATION  REQUIREMENTS  UNDER SAID LAWS, AND NEITHER SUCH SECURITIES NOR ANY
INTEREST  THEREIN  MAY  BE  OFFERED,   SOLD,  PLEDGED,   ASSIGNED  OR  OTHERWISE
TRANSFERRED  UNLESS  (1)  A  REGISTRATION  STATEMENT  WITH  RESPECT  THERETO  IS
EFFECTIVE  UNDER THE ACT AND ANY APPLICABLE  STATE  SECURITIES  LAWS, OR (2) THE
COMPANY RECEIVES AN OPINION OF COUNSEL TO THE HOLDER OF SUCH  SECURITIES,  WHICH
COUNSEL  AND OPINION  ARE  REASONABLY  SATISFACTORY  TO THE  COMPANY,  THAT SUCH
SECURITIES MAY BE OFFERED, SOLD, PLEDGED,  ASSIGNED OR TRANSFERRED IN THE MANNER
CONTEMPLATED  WITHOUT  AN  EFFECTIVE  REGISTRATION  STATEMENT  UNDER  THE ACT OR
APPLICABLE STATE SECURITIES LAWS.

THE TRANSFER OF THIS WARRANT IS RESTRICTED AS DESCRIBED HEREIN.

                                  ZHONGPIN INC.

              WARRANT FOR THE PURCHASE OF UP TO ________ SHARES OF
                    COMMON STOCK, PAR VALUE $0.001 PER SHARE

NO. PW-[___]                                                     ________ SHARES

         THIS  CERTIFIES  that,  for  value  received,  _______________  with an
address   at   _________________________________________________________________
(including  any  transferee,  the  "Holder"),  is entitled to subscribe  for and
purchase from Zhongpin Inc., a Delaware  corporation (the  "Company"),  upon the
terms and conditions  set forth herein,  at any time or from time to time before
5:00 P.M.,  New York time, on January 30, 2011 (the  "Exercise  Period"),  up to
_____________  (_____ ) shares of Common Stock at an initial  exercise price per
share equal to $5.50,  subject to  adjustment  pursuant to the terms hereof (the
"Exercise  Price").  As used  herein,  the term  "this  Warrant"  shall mean and
include  this  Warrant  and  any  Warrant  or  Warrants  hereafter  issued  as a
consequence  of the  exercise or  transfer of this  Warrant in whole or in part.
This  Warrant is one of a series of warrants of like tenor issued by the Company
pursuant  to an  Amendment  dated as of December  __,  2006 to the  Registration
Rights  Agreement (as defined  below) among the Company and the investors  named
therein and initially  covering an aggregate of _________ shares of Common Stock
(collectively, the "Company Warrants").

                                        1
<PAGE>

         The number of shares of Common  Stock  issuable  upon  exercise of this
Warrant (the "Warrant  Shares") and the Exercise Price may be adjusted from time
to time as hereinafter set forth.

         1.       (a)      This Warrant may be  exercised  during  the  Exercise
Period as to all or a lesser number of whole Warrant  Shares by the surrender of
this  Warrant  (with the Exercise  Form  attached  hereto duly  executed) to the
Company at the offices of the Company's agent, The Bank of New York, 101 Barclay
Street,  11 East,  New York New York 10286,  Attention:  __________,  or at such
other  place  as is  designated  in  writing  by the  Company,  together  with a
certified  or bank  cashier's  check  payable to the order of the  Company in an
amount equal to the Exercise  Price  multiplied by the number of Warrant  Shares
for which this Warrant is being exercised.

                  (b)      This  Warrant  may also be  exercised  by the  Holder
through a cashless exercise, as described in this Section 1(b). This Warrant may
be exercised,  in whole or in part, by (i) the delivery to the Company of a duly
executed  Exercise Form specifying the number of Warrant Shares to be applied to
such exercise, and (ii) the surrender to a common carrier for overnight delivery
to the Company, or as soon as practicable following the date the Holder delivers
the  Exercise  Form to the  Company,  of  this  Warrant  (or an  indemnification
undertaking  with  respect  to this  Warrant  in the case of its loss,  theft or
destruction). The number of shares of Common Stock to be issued upon exercise of
this Warrant pursuant to this Section 1(b) shall equal the value of this Warrant
(or the portion thereof being  canceled)  computed as of the date of delivery of
this Warrant to the Company using the following formula:

                  X =      Y(A-B)
                           ------
                             A

     where:

                  X = the  number of shares of Common  Stock to be issued to the
                      Holder under this Section 1(b);
                  Y = the number of Warrant  Shares  identified  in the Exercise
                      Form as being applied to the subject exercise;
                  A = the Current Market Price on such date; and
                  B = the Exercise Price on such date

         For purposes of this Section 1(b), the "CURRENT MARKET PRICE" per share
of Common Stock on any day shall mean:  (i) if the principal  trading market for
such securities is a national or regional securities exchange, the closing price
on such exchange on such day; or (ii) if sales prices for shares of Common Stock
are reported by the NASDAQ National Market System or NASDAQ Capital Market (or a
similar  system then in use),  the last  reported  sales price  (regular way) so
reported on such day; or (iii) if neither (i) nor (ii) above are applicable, and
if  bid  and  ask  prices  for  shares  of  Common  Stock  are  reported  in the
over-the-counter  market by NASDAQ  (or,  if not so  reported,  by the  National
Quotation Bureau), the average of the high bid and low ask prices so reported on
such day.  Notwithstanding the foregoing, if there is no reported closing price,
last reported  sales price,  or bid and ask prices,  as the case may be, for the
day in question,  then the Current  Market Price shall be  determined  as of the
latest date prior to such day for which such closing price,  last reported sales
price,  or bid and ask prices,  as the case may be, are

                                        2
<PAGE>

available,  unless such securities have not been traded on an exchange or in the
over-the-counter  market  for 30 or more  days  immediately  prior to the day in
question,  in which case the Current  Market Price shall be  determined  in good
faith by, and reflected in a formal resolution of, the Board of Directors of the
Company.

         The Company  acknowledges  and agrees  that this  Warrant was issued on
December __, 2006 (the "Issuance Date"). Consequently,  the Company acknowledges
and agrees that,  if the Holder  conducts a cashless  exercise  pursuant to this
Section  1(b),  the period  during  which the Holder held this  Warrant may, for
purposes of Rule 144  promulgated  under the  Securities Act of 1933, as amended
(the "Act"), be "tacked" to the period during which the Holder holds the Warrant
Shares received upon such cashless exercise.

         Notwithstanding  the  foregoing,  the  Holder  may  conduct a  cashless
exercise  pursuant to this Section 1(b) only after the first  anniversary of the
Issuance Date, and then only in the event that a registration statement covering
the resale of the Warrant Shares is not then effective and available for resales
at the time that the Holder wishes to conduct such cashless exercise.

         2.       Upon each exercise of the Holder's rights to purchase  Warrant
Shares,  the Holder  shall be deemed to be the  holder of record of the  Warrant
Shares issuable upon such exercise,  notwithstanding  that the transfer books of
the  Company  shall then be closed or  certificates  representing  such  Warrant
Shares shall not then have been  actually  delivered  to the Holder.  As soon as
practicable  after each such exercise of this  Warrant,  the Company shall issue
and deliver to the Holder a certificate or  certificates  for the Warrant Shares
issuable  upon  such  exercise,  registered  in the  name of the  Holder  or its
designee.  If this Warrant  should be exercised in part only, the Company shall,
upon  surrender  of this  Warrant  for  cancellation,  execute and deliver a new
Warrant  evidencing  the right of the  Holder to  purchase  the  balance  of the
Warrant Shares (or portions thereof) subject to purchase hereunder.

                  IF BY THE THIRD TRADING DAY FOLLOWING  DELIVERY OF AN EXERCISE
FORM  ("DELIVERY  DATE") THE  COMPANY  FAILS TO DELIVER THE  REQUIRED  NUMBER OF
WARRANT  SHARES IN THE  MANNER  REQUIRED  PURSUANT  TO THIS  SECTION 2, THEN THE
HOLDER WILL HAVE THE RIGHT TO RESCIND SUCH EXERCISE.

                  If by the  Delivery  Date the  Company  fails to  deliver  the
required  number of  Warrant  Shares in the  manner  required  pursuant  to this
Section  2, and if after  such date and  prior to the  receipt  of such  Warrant
Shares, shares of Common Stock are purchased by or for the account of the Holder
to deliver in  satisfaction  of a sale by the Holder of the Warrant Shares which
the Holder  anticipated  receiving  upon such  exercise (a  "Buy-In"),  then the
Company shall (1) pay in cash to the Holder the amount by which (x) the Holder's
total purchase price (including brokerage commissions, if any) for the shares of
Common Stock so purchased exceeds (y) the amount obtained by multiplying (A) the
number of Warrant  Shares that the Company was required to deliver to the Holder
in connection with such exercise by (B) the closing price of the Common Stock on
the date the Exercise  Form was  delivered  and (2) at the option of the Holder,
either  reinstate  the number of Warrant  Shares for which such exercise was not
honored or deliver to the Holder the number of shares of Common Stock that would
have been issued had the Company timely  complied with its exercise and delivery
obligations

                                        3
<PAGE>

hereunder.  The Holder shall provide the Company  written notice  indicating the
amounts payable to the Holder in respect of the Buy-In.

         3.       (a)      Any Warrants issued upon the registration of transfer
or exercise in part of this Warrant shall be numbered and shall be registered in
a Warrant  Register as they are issued.  The Company  shall be entitled to treat
the  registered  holder of any Warrant on the  Warrant  Register as the owner in
fact thereof for all purposes and shall not be bound to recognize  any equitable
or other claim to or interest in such  Warrant on the part of any other  person,
and shall not be liable for any  registration  or transfer of Warrants which are
registered  or to be  registered  in the name of a fiduciary or the nominee of a
fiduciary  unless made with the actual  knowledge that a fiduciary or nominee is
committing a breach of trust in requesting  such  registration  or transfer,  or
with the knowledge of such facts that its  participation  therein amounts to bad
faith.  The  transfer  of this  Warrant  may be  registered  on the books of the
Company  upon  delivery  thereof  duly  endorsed  by the  Holder  or by his duly
authorized  attorney or  representative,  or accompanied  by proper  evidence of
succession,  assignment or authority to transfer. In all cases of transfer by an
attorney, executor, administrator,  guardian or other legal representative,  due
authority  shall be produced.  Upon any  registration  of transfer,  the Company
shall  deliver a new Warrant or Warrants to the person  entitled  thereto.  This
Warrant  may be  exchanged,  at the option of the Holder  thereof,  for  another
Warrant,  or other  Warrants  of  different  denominations,  of like  tenor  and
representing  in the  aggregate  the right to  purchase a like number of Warrant
Shares  (or  portions  thereof),  upon  surrender  to the  Company  or its  duly
authorized agent.  Notwithstanding the foregoing,  the Company may require prior
to  registering  any  transfer  of a Warrant an  opinion  of counsel  reasonably
satisfactory  to the Company that such transfer  complies with the provisions of
the Act, and the rules and regulations thereunder.

                  (b)      The Holder  acknowledges  that he has been advised by
the  Company  that  neither  this  Warrant  nor the  Warrant  Shares  have  been
registered  under the Act, that this Warrant is being or has been issued and the
Warrant Shares may be issued on the basis of the statutory exemption provided by
Section 4(2) of the Act or Rule 506 of Regulation D promulgated  thereunder,  or
both,  relating to transactions by an issuer not involving any public  offering.
The Holder  acknowledges  that he has been  informed  by the  Company  of, or is
otherwise  familiar with, the nature of the  limitations  imposed by the Act and
the  rules  and  regulations  thereunder  on  the  transfer  of  securities.  In
particular,  the Holder  agrees  that no sale,  assignment  or  transfer of this
Warrant or the Warrant  Shares  issuable upon exercise  hereof shall be valid or
effective,  and the Company shall not be required to give any effect to any such
sale,  assignment  or transfer,  unless (i) the sale,  assignment or transfer of
this  Warrant  or such  Warrant  Shares is  registered  under the Act,  it being
understood  that  neither this  Warrant nor such  Warrant  Shares are  currently
registered  for sale and that the Company has no  obligation  or intention to so
register this Warrant or such Warrant Shares except as specifically provided for
in that certain  Registration  Rights Agreement dated as of January 30, 2006, as
amended,  by and among the Company,  the Holder and certain  other  parties (the
"Registration  Rights  Agreement"),  or (ii) this Warrant or such Warrant Shares
are sold,  assigned or transferred in accordance with all the  requirements  and
limitations of Rule 144 under the Act, it being  understood that Rule 144 is not
available at the time of the  original  issuance of this Warrant for the sale of
this Warrant or such Warrant Shares and that there can be no assurance that Rule
144  sales  will be  available  at any

                                        4
<PAGE>

subsequent time, or (iii) such sale, assignment, or transfer is otherwise exempt
from registration under the Act in the opinion of counsel reasonably  acceptable
to the Company.

         4.       The Company shall at all times reserve and keep  available out
its  authorized and unissued  Common Stock,  solely for the purpose of providing
for the exercise of the rights to purchase all Warrant Shares  granted  pursuant
to the  Warrants,  such number of shares of Common Stock as shall,  from time to
time, be sufficient  therefor.  The Company  covenants that all shares of Common
Stock issuable upon exercise of this Warrant, upon receipt by the Company of the
full  Exercise   Price   therefor,   shall  be  validly   issued,   fully  paid,
nonassessable, and free of preemptive rights.

         5.       (a)      In case the  Company shall at any time after the date
the Warrants were first issued (i) declare a dividend on the outstanding  Common
Stock payable in shares of its capital  stock,  (ii)  subdivide the  outstanding
Common Stock,  (iii) combine the outstanding  Common Stock into a smaller number
of shares, or (iv) issue any shares of its capital stock by  reclassification of
the Common Stock  (including  any such  reclassification  in  connection  with a
consolidation  or merger in which the  Company is the  continuing  corporation),
then,  in each case,  the  Exercise  Price,  and the  number of  Warrant  Shares
issuable upon exercise of this Warrant, in effect at the time of the record date
for such dividend or of the effective date of such  subdivision,  combination or
reclassification,  shall be  proportionately  adjusted so that the Holder  after
such time shall be entitled to receive the  aggregate  number and kind of shares
which,  if such Warrant had been  exercised  immediately  prior to such time, he
would have owned upon such  exercise  and been  entitled to receive by virtue of
such dividend,  subdivision,  combination or  reclassification.  Such adjustment
shall be made successively whenever any event listed above shall occur.

                  (b)      In case the Company  shall issue or fix a record date
for the issuance to all holders of Common Stock of rights,  options, or warrants
to subscribe for or purchase  Common Stock (or  securities  convertible  into or
exchangeable  for Common  Stock) at a price per share (or having a conversion or
exchange price per share, if a security  convertible  into or  exchangeable  for
Common  Stock) less than the then  applicable  Exercise  Price per share on such
record  date,  then,  in each case,  the  Exercise  Price  shall be  adjusted by
multiplying the Exercise Price in effect  immediately  prior to such record date
by a fraction,  the  numerator  of which shall be the number of shares of Common
Stock  outstanding on such record date plus the number of shares of Common Stock
which the aggregate offering price of the total number of shares of Common Stock
so to be offered (or the aggregate  initial  conversion or exchange price of the
convertible or exchangeable  securities so to be offered) would purchase at such
Exercise  Price and the  denominator  of which  shall be the number of shares of
Common  Stock  outstanding  on such  record  date plus the number of  additional
shares of Common Stock to be offered for subscription or purchase (or into which
the  convertible  or  exchangeable  securities  so to be offered  are  initially
convertible or  exchangeable).  Such  adjustment  shall become  effective at the
close of business on such record date;  provided,  however,  that, to the extent
the shares of Common Stock (or securities  convertible  into or exchangeable for
shares  of  Common  Stock)  are not  delivered,  the  Exercise  Price  shall  be
readjusted after the expiration of such rights,  options,  or warrants (but only
with respect to warrants exercised after such expiration), to the Exercise Price
which would then be in effect had the adjustments made upon the issuance of such
rights,  options,  or warrants

                                        5
<PAGE>

been  made  upon the basis of  delivery  of only the  number of shares of Common
Stock (or  securities  convertible  into or  exchangeable  for  shares of Common
Stock)  actually  issued.  In  case  any  subscription  price  may be  paid in a
consideration part or all of which shall be in a form other than cash, the value
of such  consideration  shall be as  determined  in good  faith by the  board of
directors of the Company, whose determination shall be conclusive.

                  (c)      In case the Company  shall  distribute to all holders
of Common Stock (including any such distribution made to the stockholders of the
Company in connection with a consolidation or merger in which the Company is the
continuing corporation) evidences of its indebtedness, cash (other than any cash
dividend which, together with any cash dividends paid within the 12 months prior
to the  record  date  for such  distribution,  does  not  exceed  5% of the then
applicable  Exercise Price at the record date for such  distribution)  or assets
(other than  distributions  and dividends payable in shares of Common Stock), or
rights,  options or  warrants to  subscribe  for or purchase  Common  Stock,  or
securities   convertible  into  or  exchangeable  for  shares  of  Common  Stock
(excluding  those with  respect to the  issuance of which an  adjustment  of the
Exercise Price is provided pursuant to Section 5(b) hereof), then, in each case,
the Exercise Price shall be adjusted by multiplying the Exercise Price in effect
immediately  prior to the  record  date for the  determination  of  stockholders
entitled to receive  such  distribution  by a fraction,  the  numerator of which
shall be the then  applicable  Exercise  Price per share of Common Stock on such
record  date,  less the fair market value (as  determined  in good faith by, and
reflected  in a formal  resolution  of, the board of  directors  of the Company,
whose determination shall be conclusive absent manifest error) of the portion of
the evidences of indebtedness or assets so to be distributed, or of such rights,
options or warrants or convertible or exchangeable securities,  or the amount of
such cash,  applicable to one share,  and the denominator of which shall be such
Exercise Price per share of Common Stock. Such adjustment shall become effective
at the close of business on such record date.

                  (d)      No adjustment in the Exercise Price shall be required
if such adjustment is less than $.01;  provided,  however,  that any adjustments
which by  reason  of this  Section  5(d) are not  required  to be made  shall be
carried  forward  and taken  into  account  in any  subsequent  adjustment.  All
calculations  under this  Section 5 shall be made to the nearest  cent or to the
nearest one-thousandth of a share, as the case may be.

                  (e)      In any case in which  this  Section  5 shall  require
that an adjustment in the Exercise  Price be made  effective as of a record date
for a specified event,  the Company may elect to defer,  until the occurrence of
such event,  issuing to the Holder,  if the Holder  exercised this Warrant after
such  record  date,  the  shares of Common  Stock,  if any,  issuable  upon such
exercise over and above the shares of Common Stock,  if any,  issuable upon such
exercise on the basis of the Exercise Price in effect prior to such  adjustment;
provided,  however,  that the Company  shall deliver to the Holder a due bill or
other  appropriate  instrument  evidencing  the  Holder's  right to receive such
additional shares upon the occurrence of the event requiring such adjustment.

                  (f)      Upon  each  adjustment  of the  Exercise  Price  as a
result of the  calculations  made in Sections 5(b) or 5(c) hereof,  this Warrant
shall thereafter evidence the right to purchase,

                                        6
<PAGE>

at the adjusted Exercise Price, that number of shares (calculated to the nearest
thousandth)  obtained by multiplying (A) the number of shares  purchasable  upon
exercise  of this  Warrant  prior  to such  adjustment  by (B) a  fraction,  the
numerator of which is the Exercise Price in effect prior to such  adjustment and
the denominator of which is the Exercise Price in effect  immediately after such
adjustment.

                  (g)      Whenever  there shall be an adjustment as provided in
this Section 5, the Company shall  promptly  cause written  notice thereof to be
sent by registered mail,  postage prepaid,  to the Holder,  at its address as it
shall appear in the Warrant  Register,  which notice shall be  accompanied by an
officer's  certificate  setting forth the number of Warrant  Shares  purchasable
upon the exercise of this Warrant and the Exercise  Price after such  adjustment
and setting forth a brief  statement of the facts  requiring such adjustment and
the  computation  thereof,  which  officer's  certificate  shall  be  conclusive
evidence of the correctness of any such adjustment absent manifest error.

                  (h)      The Company shall not be required to issue  fractions
of  shares  of  Common  Stock or other  capital  stock of the  Company  upon the
exercise of this  Warrant.  If any  fraction of a share would be issuable on the
exercise of this Warrant (or  specified  portions  thereof),  the Company  shall
purchase  such  fraction for an amount in cash equal to the same fraction of the
Exercise  Price of such share of Common  Stock on the date of  exercise  of this
Warrant.

         6.       (a)      In case of any  consolidation  or combination with or
merger of the Company with or into another  corporation  or entity (other than a
merger,  consolidation  or  combination in which the Company is the surviving or
continuing corporation),  or in case of any sale, lease or conveyance to another
corporation,  entity or person of the  property  and assets of any nature of the
Company as an entirety or substantially as an entirety,  or any compulsory share
exchange,  pursuant to which share  exchange the Common Stock is converted  into
other  securities,  cash  or  other  property  (collectively  an  "Extraordinary
Event"),  then,  as  a  condition  of  such  reorganization,   reclassification,
consolidation,  merger, sale, transfer or other disposition, lawful and adequate
provision  shall be made whereby the Holder shall  thereafter  have the right to
purchase  and receive  upon the basis and upon the terms and  conditions  herein
specified and in lieu of the Warrant  Shares  immediately  theretofore  issuable
upon  exercise of this  Warrant,  such shares of stock,  securities or assets as
would have been  issuable or payable with respect to or in exchange for a number
of Warrant Shares equal to the number of Warrant Shares immediately  theretofore
issuable upon exercise of this Warrant,  had such Extraordinary  Event not taken
place, and in any such case appropriate  provision shall be made with respect to
the rights and  interests  of the Holder to the end that the  provisions  hereof
(including, without limitation,  provision for adjustment of the Exercise Price)
shall  thereafter be applicable,  as nearly  equivalent as may be practicable in
relation to any shares of stock,  securities  or assets  thereafter  deliverable
upon the exercise  hereof.  The Company shall not effect any such  Extraordinary
Event  unless  prior to or  simultaneously  with the  consummation  thereof  the
successor   corporation  (if  other  than  the  Company)   resulting  from  such
Extraordinary Event shall assume the obligation to deliver to the Holder, at the
last address of the Holder appearing on the books of the Company, such shares of
stock, securities or assets as, in accordance with the foregoing provisions, the
Holder  may be

                                        7
<PAGE>

entitled  to  purchase,  and the  other  obligations  under  this  Warrant.  The
provisions of this paragraph shall  similarly apply to successive  Extraordinary
Events.

                  (b)      In  case of any  reclassification  or  change  of the
shares of Common Stock  issuable  upon  exercise of this  Warrant  (other than a
change in par  value or from no par  value to a  specified  par  value,  or as a
result of a subdivision or  combination,  but including any change in the shares
into two or more classes or series of shares),  or in case of any consolidation,
combination or merger of another corporation or entity into the Company in which
the   Company  is  the   continuing   corporation   and  in  which  there  is  a
reclassification  or change  (including a change to the right to receive cash or
other property) of the shares of Common Stock (other than a change in par value,
or from no par value to a specified  par value,  or as a result of a subdivision
or combination,  but including any change in the shares into two or more classes
or series of shares), the Holder shall have the right thereafter to receive upon
exercise of this Warrant solely the kind and amount of shares of stock and other
securities,  property or cash, or any combination  thereof  receivable upon such
reclassification,  change,  consolidation,  combination or merger by a holder of
the  number of shares of Common  Stock for which  this  Warrant  might have been
exercised  immediately prior to such  reclassification,  change,  consolidation,
combination  or  merger.  Thereafter,  appropriate  provision  shall be made for
adjustments,  which  shall  be  as  nearly  equivalent  as  practicable  to  the
adjustments in Section 5.

                  (c)      The  above   provisions   of  this  Section  6  shall
similarly apply to successive  reclassifications and changes of shares of Common
Stock and to successive consolidations,  combinations, mergers, sales, leases or
conveyances.

         7.       In case at any time the Company shall propose to:

                  (a)      pay any dividend or make any  distribution  on shares
of Common Stock in shares of Common Stock or make any other distribution  (other
than regularly  scheduled  cash dividends  which are not in a greater amount per
share than the most recent such cash  dividend) to all holders of Common  Stock;
or

                  (b)      issue any rights, warrants or other securities to all
holders of Common  Stock  entitling  them to purchase any  additional  shares of
Common Stock or any other rights, warrants or other securities; or

                  (c)      effect any  reclassification or change of outstanding
shares of Common Stock, or any consolidation,  merger, sale, lease or conveyance
of property or other Extraordinary Event; or

                  (d)      effect any liquidation,  dissolution or winding-up of
the Company; or

                  (e)      take any other action which would cause an adjustment
to the Exercise Price;

                                        8
<PAGE>

then,  and in any one or more of such  cases,  the  Company  shall give  written
notice  thereof,  by  registered  mail,  postage  prepaid,  to the Holder at the
Holder's address as it shall appear in the Warrant Register,  mailed at least 15
days prior to (i) the date as of which the holders of record of shares of Common
Stock to be  entitled  to  receive  any  such  dividend,  distribution,  rights,
warrants or other  securities are to be  determined,  (ii) the date on which any
such   reclassification,   change  of   outstanding   shares  of  Common  Stock,
consolidation,   merger,  sale,  lease,  conveyance  of  property,  liquidation,
dissolution  or winding-up is expected to become  effective,  and the date as of
which it is expected  that  holders of record of shares of Common Stock shall be
entitled to exchange  their shares for  securities  or other  property,  if any,
deliverable   upon  such   reclassification,   change  of  outstanding   shares,
consolidation,   merger,  sale,  lease,  conveyance  of  property,  liquidation,
dissolution, or winding-up, or (iii) the date of such action which would require
an adjustment to the Exercise Price.

         8.       The  issuance  of any  shares  or  other  securities  upon the
exercise of this Warrant,  and the delivery of certificates or other instruments
representing  such shares or other  securities,  shall be made without charge to
the Holder for any tax or other charge in respect of such issuance.  The Company
shall not,  however,  be required to pay any tax which may be payable in respect
of any transfer  involved in the issue and delivery of any certificate in a name
other than that of the Holder and the Company  shall not be required to issue or
deliver any such certificate  unless and until the person or persons  requesting
the issue thereof shall have paid to the Company the amount of such tax or shall
have established to the satisfaction of the Company that such tax has been paid.

         9.       Unless   registered   pursuant  to  the  Registration   Rights
Agreement,  the Warrant  Shares  issued upon  exercise of this Warrant  shall be
subject to a stop transfer order and the certificate or certificates  evidencing
such Warrant Shares shall bear the following legend:

         "THE SHARES  REPRESENTED BY THIS  CERTIFICATE  HAVE NOT BEEN REGISTERED
         UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"),  OR ANY STATE
         SECURITIES  LAWS, AND NEITHER SUCH SECURITIES NOR ANY INTEREST  THEREIN
         MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED UNLESS
         (1) A REGISTRATION  STATEMENT WITH RESPECT  THERETO IS EFFECTIVE  UNDER
         THE ACT AND ANY APPLICABLE  STATE  SECURITIES  LAWS, OR (2) THE COMPANY
         RECEIVES AN OPINION OF COUNSEL TO THE HOLDER OF SUCH SECURITIES,  WHICH
         COUNSEL AND OPINION ARE REASONABLY  SATISFACTORY  TO THE COMPANY,  THAT
         SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED,  ASSIGNED OR TRANSFERRED
         IN THE MANNER CONTEMPLATED WITHOUT AN EFFECTIVE  REGISTRATION STATEMENT
         UNDER THE ACT OR APPLICABLE STATE SECURITIES LAWS."

         10.      Upon  receipt of evidence  satisfactory  to the Company of the
loss, theft, destruction or mutilation of any Warrant (and upon surrender of any
Warrant if  mutilated),  the

                                        9
<PAGE>

Company  shall  execute and deliver to the Holder  thereof a new Warrant of like
date, tenor and denomination.

         11.      The holder of this Warrant shall not have solely on account of
such status,  any rights of a  stockholder  of the Company,  either at law or in
equity, or to any notice of meetings of stockholders or of any other proceedings
of the Company, except as provided in this Warrant.

         12.      Any term of this  Warrant  may be amended  or waived  upon the
written consent of the Company and the holders of Company Warrants  representing
at least  50% of the  number  of shares of  Common  Stock  then  subject  to all
outstanding Company Warrants (the "Majority  Holders");  provided,  that (x) any
such amendment or waiver must apply to all Company Warrants;  and (y) the number
of Warrant Shares  subject to this Warrant,  the Exercise Price and the Exercise
Period may not be  amended,  and the right to exercise  this  Warrant may not be
altered or waived, without the written consent of the Holder.

         13.      This Warrant has been  negotiated and consummated in the State
of New York and shall be governed by, and construed in accordance  with the laws
of the State of New York applicable to contracts made and performed  within such
State, without regard to principles governing conflicts of law. The Company and,
by accepting this Warrant, the Holder, each irrevocably submits to the exclusive
jurisdiction  of the courts of the State of New York  located in New York County
and the United States  District Court for the Southern  District of New York for
the purpose of any suit,  action,  proceeding or judgment relating to or arising
out of this Warrant and the transactions contemplated hereby. Service of process
in connection  with any such suit,  action or  proceeding  may be served on each
party hereto  anywhere in the world by the same methods as are specified for the
giving of notices under the Securities Purchase  Agreement.  The Company and, by
accepting  this  Warrant,   the  Holder,   each  irrevocably   consents  to  the
jurisdiction of any such court in any such suit, action or proceeding and to the
laying of venue in such court.  The Company and, by accepting this Warrant,  the
Holder, each irrevocably waives any objection to the laying of venue of any such
suit,  action or proceeding  brought in such courts and  irrevocably  waives any
claim that any such  suit,  action or  proceeding  brought in any such court has
been  brought  in an  inconvenient  forum.  EACH  OF  THE  COMPANY  AND,  BY ITS
ACCEPTANCE HEREOF, THE HOLDER HEREBY WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY
IN ANY LITIGATION  WITH RESPECT TO THIS WARRANT AND REPRESENTS  THAT COUNSEL HAS
BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.

         [14.     The Company shall not effect the exercise of this Warrant, and
no person who is a holder of this Warrant  shall have the right to exercise this
Warrant,  to the extent that after giving effect to such  exercise,  such person
(together with such person's  affiliates)  would  beneficially  own in excess of
9.999% of the shares of the Common Stock  outstanding  immediately  after giving
effect to such exercise.  For purposes of the foregoing sentence,  the aggregate
number of  shares of Common  Stock  beneficially  owned by such  person  and its
affiliates  shall include,  without  limitation,  the number of shares of Common
Stock  issuable  upon  exercise  of this  Warrant  with  respect  to  which  the
determination of such sentence is being made, but shall exclude shares of Common
Stock which would be issuable  upon (i) exercise of the  remaining,

                                       10
<PAGE>

unexercised  portion of this Warrant  beneficially  owned by such person and its
affiliates  and (ii) exercise or conversion of the  unexercised  or  unconverted
portion of any other securities of the Company beneficially owned by such person
and its affiliates  (including,  without limitation,  shares of Preferred Stock,
any  debentures,  convertible  notes or  other  convertible  preferred  stock or
warrants)  subject to a limitation on  conversion  or exercise  analogous to the
limitation contained herein. Except as set forth in the preceding sentence,  for
purposes  of  this  paragraph,  beneficial  ownership  shall  be  calculated  in
accordance with Section 13(d) of the Exchange Act. For purposes of this Warrant,
in determining  the number of  outstanding  shares of Common Stock, a Holder may
rely on the number of outstanding shares of Common Stock as reflected in (1) the
Company's  most  recent  Form 10-Q,  Form 10-K or other  public  filing with the
Commission,  as the case may be, (2) a more recent  public  announcement  by the
Company,  or (3) any other notice by the Company or its transfer  agent  setting
forth the number of shares of Common  Stock  outstanding.  For any reason at any
time,  upon the  written  or oral  request of the  Holder of this  Warrant,  the
Company  shall within five  business  days confirm  orally and in writing to the
Holder of this Warrant the number of shares of Common Stock then outstanding. In
any case, the number of  outstanding  shares of Common Stock shall be determined
after giving  effect to the  conversion or exercise of securities of the Company
by the Holder of this Warrant and its affiliates since the date as of which such
number of  outstanding  shares of Common Stock was  reported.  In effecting  the
exercise  of  this  Warrant,  the  Company  shall  be  entitled  to  rely  on  a
representation  by the Holder of this Warrant as to the number of shares that it
beneficially owns for purposes of the above 9.999% limitation calculation.]*

Dated:  _________, 200_

                                        ZHONGPIN INC.

                                        By:
                                           -------------------------------------
                                           Name:
                                           Title:

------------------
* Section 14 shall be deleted from any Warrant  issued by the Company to Special
  Situations Fund III QP, L.P. or its affiliates.

                                       11

<PAGE>

                                  ZHONGPIN INC.

                               FORM OF ASSIGNMENT

             (To be executed by the registered holder if such holder
                   desires to transfer the attached Warrant.)

To:      Zhongpin Inc.
         21 Changshe Road
         Changge City, Henan Province
         The People's Republic of China

         Attention:   Secretary

         FOR  VALUE  RECEIVED,   _______________   hereby  sells,  assigns,  and
transfers  unto  _______________  that certain  Warrant  (Number  PW-______)  to
purchase  __________  shares of Common  Stock,  par value  $0.001 per share,  of
Zhongpin Inc. (the  "Company"),  together  with all right,  title,  and interest
therein,    and    does    hereby    irrevocably    constitute    and    appoint
________________________  attorney to transfer  such Warrant on the books of the
Company, with full power of substitution.

Dated:
       --------------------

                                        Signature:
                                                  ------------------------------

                                     NOTICE:

         The signature on the foregoing  Assignment  must correspond to the name
as written upon the face of this Warrant in every particular, without alteration
or enlargement or any change whatsoever.

<PAGE>

                                  ZHONGPIN INC.

                                  EXERCISE FORM

         (To be completed and signed only upon exercise of the Warrants)

To:      Zhongpin Inc.
         21 Changshe Road
         Changge City, Henan Province
         The People's Republic of China

         Attention: Secretary

         The  undersigned  hereby  exercises  his  or  its  rights  to  purchase
___________  Warrant Shares  covered by the within  Warrant and tenders  payment
herewith  in the  amount  of  $_________  by  [tendering  cash or  delivering  a
certified  check or bank cashier's  check,  payable to the order of the Company]
[surrendering  ______  shares of Common  Stock  received  upon  exercise  of the
attached  Warrant,  which  shares  have a  Current  Market  Price  equal to such
payment] in accordance  with the terms thereof,  and requests that  certificates
for such securities be issued in the name of, and delivered to:

                                        ----------------------------------------

                                        ----------------------------------------

                                        ----------------------------------------
                                        (Print Name, Address and Social Security
                                              or Tax Identification Number)

and,  if such  number of  Warrant  Shares  shall not be all the  Warrant  Shares
covered by the within Warrant, that a new Warrant for the balance of the Warrant
Shares covered by the within Warrant be registered in the name of, and delivered
to, the undersigned at the address stated below.

Dated: ____________, ________           Name:
                                             -----------------------------------
                                                       (Please Print)

                                        Address:
                                                --------------------------------
                                                --------------------------------
                                                --------------------------------

                                                --------------------------------
                                                          (Signature)Exhibit 10.1

 

EXHIBIT 10.1

CONSULTING SERVICES AGREEMENT

     This Consulting Services Agreement (this “Agreement”) is made on December 30, 2006 (the
“Effective Date”) by and between Wendell Wierenga, Ph.D., 18608 Via Catania, Rancho Santa Fe,
California 92091 (“Consultant”) and Neurocrine Biosciences, Inc., 12790 El Camino Real, San Diego,
California 92130 (“Neurocrine”).

     WHEREAS, Neurocrine is engaged in the research and development of human pharmaceutical
products;

     WHEREAS, Consultant has expertise in the area of research and development;

     WHEREAS, Neurocrine wishes to engage the Consultant to provide the services set forth below on
the terms and conditions set forth herein and the Consultant wishes to be so retained.

     NOW THEREFORE, in consideration of the premises and of the mutual covenants, conditions and
agreements contained herein, the parties agree as follows:

ARTICLE ONE

CONSULTING SERVICES

1.1 Engagement. Neurocrine hereby agrees to engage the Consultant to perform the services
set forth in paragraph 1.2 hereof for the benefit of Neurocrine and the Consultant agrees to
perform such services on the terms and conditions set forth herein.

1.2 Services to be Performed by Consultant. During the term of this Agreement, Consultant
shall, under the direction of Gary A. Lyons, President and Chief Executive Officer, perform the
services set forth below (collectively, the “Services”). Consultant shall:

     (a) advise on matters relating to Neurocrine’s research and development programs (the
“Field”); and

     (b) perform such additional Services as mutually agreed upon by the parties.

1.3 Reporting. Neurocrine shall have the right to request written reports at any time
during the term of this Agreement describing the progress, status of, data, costs and other matters
pertaining to the Services as Neurocrine shall request. All such information arising out of the
performance of the Services under this Agreement may be freely utilized by Neurocrine in any manner
desired.

1.4 Location. The Services shall be performed at such place or places and at such time or
times as Neurocrine and Consultant shall reasonably agree.

1.5 Time to be devoted. Consultant will provide not more than two (2) full days of
consulting per quarter. Consultant may be sought by Neurocrine over the telephone or in person at
the Consultant’s office or another reasonable location or through written correspondence, and will
involve reviewing activities and developments relating to the Field.

-1-

 

ARTICLE TWO

COMPENSATION

2.1 Compensation. In full consideration of the Consultant’s performance of the Services,
Neurocrine will pay to the Consultant twenty-five thousand ($25,000.00) per year payable in four
(4) installments of twelve thousand five hundred dollars ($12,500.00) on June 1, 2007, December 31,
2007, June 1, 2008 and December 31, 2008 for a maximum retainer of fifty thousand dollars
($50,000.00).

2.2 Reimbursement. Neurocrine will reimburse Consultant for any and all reasonable travel
related expenses (which shall be arranged and booked through Neurocrine’s on-site Travel Agent)
incurred by Consultant in connection with Consultant’s performance of the Services, provided,
however, that all such expenses must be preapproved by Neurocrine in writing. Reimbursement for
travel related expenses will not include routine travel to and from work. Reimbursable travel
expenses shall include automobile rental and other transportation expenses, hotel expenses and
meals. All requests for reimbursement for travel-related expenses must be accompanied by
documentation in form and detail sufficient to meet the requirements of the taxing authorities with
respect to recognition of business-related travel expenses for corporate tax purposes.

ARTICLE THREE

WARRANTIES AND COVENANTS

3.1 Consultant’s Warranties. The Consultant represents and warrants:

     (a) Consultant has not entered into any agreement, whether written or oral, in conflict with
this Agreement; and

     (b) Consultant has the full power and authority to enter into this Agreement.

3.2 Consultant’s Covenants. Consultant:

     (a) shall act as an independent contractor with no authority to obligate Neurocrine by
contract or otherwise and not as an employee or officer of Neurocrine;

     (b) shall exercise only such powers and perform such duties as may from time to time be vested
in Consultant or assigned to Consultant by Neurocrine;

     (c) shall perform the Services and promote the interests of Neurocrine to the best of
Consultant’s skill and ability;

     (d) shall comply with all standards of safety, take due regard and comply with the safety
regulations of Neurocrine and all statutory provisions in effect and report to Neurocrine any
incident which could give rise to unsafe working conditions or practices;

     (e) shall not assign or subcontract performance of this Agreement or any of the Services to
any person, firm, company or organization without Neurocrine’s prior written consent;

     (f) shall not recruit, solicit or induce any Neurocrine employee, client, customer or account
to terminate their employment or relationship with Neurocrine;

-2-

 

     (g) shall not, during the term of this Agreement, enter into any other agreement, whether
written or oral, which would conflict with Consultant’s obligations hereunder or engage in any
activity which relates to a business directly competing or attempting to directly compete with
Neurocrine, and provided, however, that the above shall not prevent the Consultant
from engaging in any academic research, teaching or related non-commercial activity; and

     (h) shall not initiate or participate in any communications with the United States Food and
Drug Administration, other governmental agency or foreign equivalent concerning the subject matter
hereof unless required by law or requested to do so by Neurocrine, and then, only upon prior
consultation with Neurocrine.

ARTICLE FOUR

CONFIDENTIAL INFORMATION

4.1 Confidentiality. Neurocrine Confidential Information shall mean all information
concerning Neurocrine, and/or Consultant’s Services to Neurocrine hereunder which is disclosed to
Consultant by Neurocrine or which results from, or in connection with, any Services performed by
Consultant pursuant to this Agreement or Consultant’s presence at the Neurocrine facilities.
Consultant shall, during the term of this Agreement and for a period of five (5) years thereafter,
keep all Neurocrine Confidential Information confidential and use such information only for the
purposes expressly set forth herein. Such Neurocrine Confidential Information includes, but is not
limited to, confidential or proprietary information, data and information developed by Consultant
in performing the Services, materials, know-how and other data, both technical and non-technical.

4.2 Access. Consultant agrees to limit the access to Neurocrine Confidential Information
to only those persons under Consultant’s direct control who, with Neurocrine’s knowledge and
consent, are responsible for performing the Services set forth in Article One.

4.3 Authorized Disclosure. Consultant shall have no obligation of confidentiality and
non-use with respect to any portion of Neurocrine Confidential Information which (i) is or later
becomes generally available to the public by use, publication or the like, through no act or
omission of Consultant; (ii) is obtained from a third party who had the legal right to disclose the
information to Consultant; or (iii) Consultant already possesses as evidenced by Consultant’s
written records predating receipt thereof from Neurocrine or development pursuant to the Services.

4.4 Return of Information. Upon the termination of this Agreement, Consultant will
promptly return to Neurocrine all materials, records, documents, and other Neurocrine Confidential
Information in tangible form. Consultant shall retain no copies of such materials and information
and, if requested by Neurocrine, will delete all Neurocrine Confidential Information stored in any
magnetic or optical disc or memory.

4.5 Third Party Information. Consultant shall not, in connection with the Services to be
performed under this Agreement, disclose to Neurocrine any information which is confidential or
proprietary to Consultant or any third party.

-3-

 

ARTICLE FIVE

INTELLECTUAL PROPERTY

5.1 Ownership. Consultant agrees that any information, including but not limited to
discoveries, inventions, copyright, design rights, patents, innovations, suggestions, know-how,
ideas and reports made by Consultant to Neurocrine which result from, or are related to,
information disclosed by Neurocrine to Consultant or which are developed as a result of, or in
connection with, Consultant’s Services under this Agreement shall be promptly disclosed to
Neurocrine and treated by Consultant as the sole property of Neurocrine (“Neurocrine Intellectual
Property”).

5.2 Assignment. Consultant agrees to assign to Neurocrine any rights that Consultant may
have in any Neurocrine Intellectual Property, and further agrees to assist Neurocrine (at
Neurocrine’s expense) in obtaining, enforcing and maintaining Neurocrine’s rights in and to the
Neurocrine Intellectual Property and irrevocably appoints Neurocrine and its duly authorized
officers and agents as his agents and attorneys for such purpose.

ARTICLE SIX

RELATIONSHIP OF THE PARTIES

6.1 Relationship. The relationship of Consultant to Neurocrine will be one of independent
contractor and at no time will Consultant hold itself out to be an employee of Neurocrine or
represent itself, either directly or indirectly, as being connected with or interested in the
business of Neurocrine.

6.2 No Withholding. No amount will be deducted or withheld from Neurocrine’s payment to
Consultant for state, federal or local taxes. No FICA, FUTA, SDI or state unemployment taxes will
be payable by Neurocrine on Consultant’s behalf and Consultant will be solely responsible for and
will pay such taxes.

6.3 Benefits. Consultant shall not claim the status, prerequisites or benefits of a
Neurocrine employee. Consultant agrees that Consultant is not eligible for coverage or to receive
any benefit under any Neurocrine employee benefit plan or employee compensation arrangement,
including without limitation, any and all medical and dental plans, bonus or incentive plans,
retirement benefit plans, stock plans, disability benefit plans, life insurance and any and all
other such plans or benefits. Even if Consultant were to become or be deemed to be a common-law
employee of Neurocrine, Consultant still shall not be eligible for coverage or to receive any
benefit under any Neurocrine employee benefit plan or any employee compensation arrangement with
respect to any period during which Neurocrine classified the individual as a Consultant.

6.4 Taxes/Fees and Costs/Expenses Indemnification. This Agreement constitutes a contract
for the provision of Services and not a contract for employment and, accordingly, Consultant will
be fully responsible for and will indemnify Neurocrine for and in respect of any state, local or
federal taxes or fees including without limitation, income tax withholding, employment and
self-employment taxes, FUTA, SDI and state unemployment taxes together with any other liability,
deduction, contribution, assessment or claim arising from or made in connection with the payment by
Neurocrine under this Agreement. The Consultant will further indemnify Neurocrine against all
reasonable costs and expenses and any penalty, fine or interest incurred or payable by Neurocrine
in connection with or in consequence of such liability, deduction, contribution, assessment or
claim. Neurocrine may, at its option, satisfy such
indemnity (in whole or in part) by way of deduction from the fees and/or expenses payable by
Neurocrine to Consultant hereunder.

-4-

 

6.5 Worker’s Compensation. Consultant acknowledges that if Consultant is injured while
performing work for Neurocrine hereunder, Consultant will not be covered for such injury under
Neurocrine’s insurance policies, including under any Worker’s Compensation coverage provided for
Neurocrine’s employees and further acknowledges that Consultant is solely responsible for providing
Worker’s Compensation insurance for Consultant and Consultant’s employees.

ARTICLE SEVEN

TERM AND TERMINATION

7.1 Term. This Agreement shall terminate two (2) years from the Effective Date. At the
end of the two (2) year term, this Agreement may be renewed on equivalent terms and conditions upon
the mutual written consent of the parties.

7.2 Termination. This Agreement may be terminated by either party at any time upon written
notice to the other party. In the event this Agreement shall be so terminated by either party,
upon submission to Neurocrine by Consultant of reasonable documentation of all work performed by
Consultant to such date, Consultant shall be entitled to recover payment for all work actually
performed prior to the date of termination.

7.3 Effect of Termination. Upon the termination of this Agreement, each party shall be
released from all obligations and liabilities hereunder except those arising under Articles Four
and Five.

ARTICLE EIGHT

INDEMNIFICATION AND INSURANCE

8.1 Indemnification. Consultant hereby agrees to indemnify and save harmless Neurocrine,
its officers, directors, employees and agents against all liability, obligations, claims, loss and
expense arising out of acts or omissions of the Consultant in performing the Services hereunder,
provided however, in no event will Consultant’s liability to Neurocrine hereunder exceed amounts
paid by Neurocrine to Consultant pursuant to Article Two above.

8.2 Consequential Damages. Neither party shall be liable to the other for any
consequential damages.

ARTICLE NINE

MISCELLANEOUS

9.1 Waiver. None of the terms of this Agreement may be waived except by an express
agreement in writing signed by the party against whom enforcement of such waiver is sought. The
failure or delay of either party in enforcing any of its rights under this Agreement shall not be
deemed a continuing waiver of such right.

9.2 Entire Agreement. This Agreement constitutes the entire agreement among the parties
with respect to the subject matter hereof and supersedes all prior agreements and understandings
among the parties (whether written or oral) relating to said subject matter.

-5-

 

9.3 Amendments. This Agreement may not be released, discharged, amended or modified in any
manner except by an instrument in writing signed by Consultant and a duly authorized officer of
Neurocrine.

9.4 Assignment. Neurocrine has specifically contracted for the Services of Consultant and,
therefore, Consultant may not assign or delegate Consultant’s obligations under this Agreement,
either in whole or in part, without the prior written consent of Neurocrine. Neurocrine may assign
this Agreement at any time without the prior consent of Consultant.

9.5 Severability. If any provision of this Agreement is, becomes, or is deemed invalid,
illegal or unenforceable in any jurisdiction, such provision shall be deemed amended to conform to
the applicable laws so as to be valid and enforceable, or, if it can not be so amended without
materially altering the intention of the parties hereto, it shall be stricken and the remainder of
this Agreement shall remain in full force and effect.

9.6 Headings. Article and Section headings contained in the Agreement are included for
convenience only and are not to be used in construing or interpreting this Agreement.

9.7 Counterparts. This Agreement may be executed in any number of counterparts, each of
which shall be an original and all of which together shall constitute one and the same document,
binding on all parties notwithstanding that each of the parties may have signed different
counterparts.

9.8 Governing Law. This Agreement shall be governed by and construed in accordance with
the laws of the state of California and the parties to this Agreement hereby submit to the
exclusive jurisdiction of the California courts, both state and federal.

9.9 Public Announcements. Consultant may not make any press release, statement or public
announcement that mentions or refers to Neurocrine without Neurocrine’s prior written consent.

9.10 Employment. Consultant certifies that Services furnished under this Agreement have
been furnished in full compliance with all applicable federal and state laws and regulations
relating to nondiscrimination in employment. Consultant certifies that it does not maintain any
segregated facilities.

     IN WITNESS WHEREOF, the parties have entered into this Agreement on the date first above written.

	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	CONSULTANT

 	 
	 	/s/ Wendell Wierenga, Ph.D.
 	 
	 	Name:  	Wendell Wierenga, Ph.D. 	 
	 	 	 	 	 
	 	 	 	 	 
	 	NEUROCRINE BIOSCIENCES, INC.

 	 
	 	/s/
Gary
A. Lyons
 	 
	 	By:  	Gary A. Lyons	 
	 	Title:  	President and Chief Executive Officer	 

-6-

 

	 	 	 	 	 

Exhibit A

Non-Employee Information Security Agreement

     As a contractor to Neurocrine you are advised that continued assignment in this capacity requires
you to abide by the following information security policies and that any violation of these
guidelines will result in loss of all access privileges.

1. I will not give to any other person the USER Identification or passwords which may be issued to
me to access Neurocrine’s electronic systems unless authorized in writing by the sponsoring
Neurocrine manager or the Manager of Information Protection Services.

2. I will not obtain, possess or use in any manner another person’s USER identification or
Neurocrine staff member’s password. If I do come into possession of a Neurocrine staff member’s
password I will not keep a record of it or disclose the password to any other person. I will
immediately inform the staff member of the disclosure so that the password may be changed.

3. I will not attempt to access or possess any Neurocrine financial, technical, proprietary,
customer, employee or any other information for which I am not entitled or authorized.

4. I will treat all Neurocrine information as confidential and not distribute or disseminate its
contents unless authorized according to Neurocrine policy or in writing by the appropriate
Neurocrine manager.

5. I will treat all Neurocrine data, reports, documents, manuals, programs, and listings, as well
as all other work products, as confidential and belonging exclusively to Neurocrine.

6. I will not copy, distribute or reveal the contents of all or any part of any computer program,
program documentation, system documentation, user manuals data or other assignment(s) except as so
directed by the sponsoring Neurocrine manager.

7. I will safeguard all assets assigned to me by Neurocrine and use these assets for business
purposes only.

8. I will be responsible for maintaining the security of any personal computer (MACs or PCs),
peripheral devices, or software assigned to me by Neurocrine. I will not possess or introduce any
unauthorized software on any Neurocrine computer system including MACs or PCs whether assigned or
not assigned to me.

9. I will make no attempt to enter into any Neurocrine facility, room or area for which I have not
been properly authorized. I will not abuse or misuse my authority to gain access into any
facility, room or area.

10. I will abide by all other Neurocrine Security policies, procedures, and standards developed
during the term of this Agreement.

     I have read and completely understand all of the above and will abide by these guidelines as
defined. I will direct questions concerning information security to (x7754) and concerning
facility security to (x7655).

	 	 	 	 	 
	 	 
	/s/ Wendell Wierenga, Ph.D.
 	 
	Wendell Wierenga, Ph.D. 	 
	 	 
	 

-7-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}]]